25 XP   0   0   10

Molecular Partners AG ADR
Buy, Hold or Sell?

Let's analyse Molecular Partners AG ADR together

PenkeI guess you are interested in Molecular Partners AG ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Molecular Partners AG ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Molecular Partners AG ADR

I send you an email if I find something interesting about Molecular Partners AG ADR.

Quick analysis of Molecular Partners AG ADR (30 sec.)










What can you expect buying and holding a share of Molecular Partners AG ADR? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$5.87
Expected worth in 1 year
$4.61
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
$-1.26
Return On Investment
-32.5%

For what price can you sell your share?

Current Price per Share
$3.88
Expected price per share
$0 - $4.66
How sure are you?
50%

1. Valuation of Molecular Partners AG ADR (5 min.)




Live pricePrice per Share (EOD)

$3.88

Intrinsic Value Per Share

$-30.68 - $-9.61

Total Value Per Share

$-24.81 - $-3.74

2. Growth of Molecular Partners AG ADR (5 min.)




Is Molecular Partners AG ADR growing?

Current yearPrevious yearGrowGrow %
How rich?$192.8m$277.9m-$59m-27.0%

How much money is Molecular Partners AG ADR making?

Current yearPrevious yearGrowGrow %
Making money-$17m$32.4m-$49.5m-289.7%
Net Profit Margin-1,680.4%-296.2%--

How much money comes from the company's main activities?

3. Financial Health of Molecular Partners AG ADR (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#261 / 1010

Most Revenue
#445 / 1010

Most Profit
#664 / 1010

Most Efficient
#835 / 1010

What can you expect buying and holding a share of Molecular Partners AG ADR? (5 min.)

Welcome investor! Molecular Partners AG ADR's management wants to use your money to grow the business. In return you get a share of Molecular Partners AG ADR.

What can you expect buying and holding a share of Molecular Partners AG ADR?

First you should know what it really means to hold a share of Molecular Partners AG ADR. And how you can make/lose money.

Speculation

The Price per Share of Molecular Partners AG ADR is $3.88. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Molecular Partners AG ADR.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Molecular Partners AG ADR, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.87. Based on the TTM, the Book Value Change Per Share is $-0.32 per quarter. Based on the YOY, the Book Value Change Per Share is $0.90 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Molecular Partners AG ADR.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.66-17.0%-0.53-13.5%0.9825.3%-0.18-4.7%-0.16-4.1%
Usd Book Value Change Per Share-0.66-17.0%-0.32-8.1%0.9023.1%0.143.6%0.143.5%
Usd Dividend Per Share0.000.0%0.000.0%0.010.1%0.000.0%0.000.0%
Usd Total Gains Per Share-0.66-17.0%-0.32-8.1%0.9023.3%0.143.7%0.143.5%
Usd Price Per Share4.18-5.14-10.14-13.97-18.29-
Price to Earnings Ratio-1.59--2.52--4.28--7.73--653.74-
Price-to-Total Gains Ratio-6.35--1.85-10.09--3.69--1.63-
Price to Book Ratio0.71-0.77-1.21-9.92-11.58-
Price-to-Total Gains Ratio-6.35--1.85-10.09--3.69--1.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.88
Number of shares257
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.320.14
Usd Total Gains Per Share-0.320.14
Gains per Quarter (257 shares)-81.0736.49
Gains per Year (257 shares)-324.29145.98
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-324-3341145136
20-649-6582290282
30-973-9823435428
40-1297-13064580574
50-1621-16305725720
60-1946-19546869866
70-2270-2278810141012
80-2594-2602911591158
90-2919-29261013041304
100-3243-32501114491450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%5.039.00.011.4%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%18.020.02.045.0%19.020.05.043.2%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.042.04.5%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%18.020.02.045.0%19.020.05.043.2%

Fundamentals of Molecular Partners AG ADR

About Molecular Partners AG ADR

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Fundamental data was last updated by Penke on 2024-04-11 14:56:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Molecular Partners AG ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Molecular Partners AG ADR earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • A Net Profit Margin of -1,916.7% means that $-19.17 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Molecular Partners AG ADR:

  • The MRQ is -1,916.7%. The company is making a huge loss. -2
  • The TTM is -1,680.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,916.7%TTM-1,680.4%-236.3%
TTM-1,680.4%YOY-296.2%-1,384.2%
TTM-1,680.4%5Y-1,054.4%-626.0%
5Y-1,054.4%10Y-584.8%-469.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,916.7%-200.1%-1,716.6%
TTM-1,680.4%-216.8%-1,463.6%
YOY-296.2%-288.3%-7.9%
5Y-1,054.4%-449.1%-605.3%
10Y-584.8%-605.5%+20.7%
1.1.2. Return on Assets

Shows how efficient Molecular Partners AG ADR is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • -10.0% Return on Assets means that Molecular Partners AG ADR generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Molecular Partners AG ADR:

  • The MRQ is -10.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.0%TTM-7.1%-2.9%
TTM-7.1%YOY9.1%-16.2%
TTM-7.1%5Y-12.1%+5.0%
5Y-12.1%10Y-9.4%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.0%-13.3%+3.3%
TTM-7.1%-12.8%+5.7%
YOY9.1%-11.7%+20.8%
5Y-12.1%-13.9%+1.8%
10Y-9.4%-15.7%+6.3%
1.1.3. Return on Equity

Shows how efficient Molecular Partners AG ADR is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • -11.2% Return on Equity means Molecular Partners AG ADR generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Molecular Partners AG ADR:

  • The MRQ is -11.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.2%TTM-7.9%-3.3%
TTM-7.9%YOY10.9%-18.8%
TTM-7.9%5Y-22.1%+14.2%
5Y-22.1%10Y-15.9%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.2%-16.9%+5.7%
TTM-7.9%-16.1%+8.2%
YOY10.9%-15.1%+26.0%
5Y-22.1%-19.3%-2.8%
10Y-15.9%-20.2%+4.3%

1.2. Operating Efficiency of Molecular Partners AG ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Molecular Partners AG ADR is operating .

  • Measures how much profit Molecular Partners AG ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • An Operating Margin of -1,613.2% means the company generated $-16.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Molecular Partners AG ADR:

  • The MRQ is -1,613.2%. The company is operating very inefficient. -2
  • The TTM is -1,539.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,613.2%TTM-1,539.6%-73.6%
TTM-1,539.6%YOY-287.3%-1,252.3%
TTM-1,539.6%5Y-1,002.6%-537.0%
5Y-1,002.6%10Y-558.6%-444.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,613.2%-296.2%-1,317.0%
TTM-1,539.6%-232.5%-1,307.1%
YOY-287.3%-298.2%+10.9%
5Y-1,002.6%-492.1%-510.5%
10Y-558.6%-632.4%+73.8%
1.2.2. Operating Ratio

Measures how efficient Molecular Partners AG ADR is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 16.55 means that the operating costs are $16.55 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Molecular Partners AG ADR:

  • The MRQ is 16.548. The company is inefficient in keeping operating costs low. -1
  • The TTM is 26.209. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ16.548TTM26.209-9.660
TTM26.209YOY6.504+19.705
TTM26.2095Y10.864+15.344
5Y10.86410Y4.974+5.890
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ16.5483.231+13.317
TTM26.2093.310+22.899
YOY6.5043.890+2.614
5Y10.8645.739+5.125
10Y4.9747.876-2.902

1.3. Liquidity of Molecular Partners AG ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Molecular Partners AG ADR is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.35 means the company has $13.35 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Molecular Partners AG ADR:

  • The MRQ is 13.350. The company is very able to pay all its short-term debts. +2
  • The TTM is 14.414. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.350TTM14.414-1.064
TTM14.414YOY12.904+1.510
TTM14.4145Y7.487+6.927
5Y7.48710Y8.308-0.821
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3503.890+9.460
TTM14.4144.173+10.241
YOY12.9045.344+7.560
5Y7.4876.126+1.361
10Y8.3086.448+1.860
1.3.2. Quick Ratio

Measures if Molecular Partners AG ADR is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • A Quick Ratio of 21.38 means the company can pay off $21.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Molecular Partners AG ADR:

  • The MRQ is 21.380. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.665. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.380TTM23.665-2.285
TTM23.665YOY20.730+2.935
TTM23.6655Y11.452+12.213
5Y11.45210Y10.719+0.733
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.3803.514+17.866
TTM23.6653.998+19.667
YOY20.7305.380+15.350
5Y11.4526.105+5.347
10Y10.7196.404+4.315

1.4. Solvency of Molecular Partners AG ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Molecular Partners AG ADR assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Molecular Partners AG ADR to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Molecular Partners AG ADR assets are financed with 11.1% credit (debt) and the remaining percentage (100% - 11.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Molecular Partners AG ADR:

  • The MRQ is 0.111. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.102. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.111TTM0.102+0.008
TTM0.102YOY0.118-0.016
TTM0.1025Y0.301-0.199
5Y0.30110Y0.284+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1110.339-0.228
TTM0.1020.336-0.234
YOY0.1180.271-0.153
5Y0.3010.366-0.065
10Y0.2840.389-0.105
1.4.2. Debt to Equity Ratio

Measures if Molecular Partners AG ADR is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.4% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Molecular Partners AG ADR:

  • The MRQ is 0.124. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.114. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.124TTM0.114+0.010
TTM0.114YOY0.135-0.021
TTM0.1145Y0.516-0.402
5Y0.51610Y0.449+0.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1240.388-0.264
TTM0.1140.402-0.288
YOY0.1350.335-0.200
5Y0.5160.426+0.090
10Y0.4490.461-0.012

2. Market Valuation of Molecular Partners AG ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Molecular Partners AG ADR generates.

  • Above 15 is considered overpriced but always compare Molecular Partners AG ADR to the Biotechnology industry mean.
  • A PE ratio of -1.59 means the investor is paying $-1.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Molecular Partners AG ADR:

  • The EOD is -1.474. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.588. Based on the earnings, the company is expensive. -2
  • The TTM is -2.517. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.474MRQ-1.588+0.114
MRQ-1.588TTM-2.517+0.929
TTM-2.517YOY-4.280+1.763
TTM-2.5175Y-7.725+5.209
5Y-7.72510Y-653.739+646.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.474-2.264+0.790
MRQ-1.588-2.629+1.041
TTM-2.517-2.680+0.163
YOY-4.280-4.145-0.135
5Y-7.725-6.257-1.468
10Y-653.739-6.254-647.485
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Molecular Partners AG ADR:

  • The EOD is -1.921. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.069. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.647. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.921MRQ-2.069+0.149
MRQ-2.069TTM-2.647+0.577
TTM-2.647YOY-2.351-0.296
TTM-2.6475Y-34.565+31.918
5Y-34.56510Y-20.824-13.741
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.921-2.973+1.052
MRQ-2.069-3.333+1.264
TTM-2.647-3.553+0.906
YOY-2.351-5.605+3.254
5Y-34.565-8.376-26.189
10Y-20.824-8.865-11.959
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Molecular Partners AG ADR is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.71 means the investor is paying $0.71 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Molecular Partners AG ADR:

  • The EOD is 0.661. Based on the equity, the company is cheap. +2
  • The MRQ is 0.712. Based on the equity, the company is cheap. +2
  • The TTM is 0.768. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.661MRQ0.712-0.051
MRQ0.712TTM0.768-0.056
TTM0.768YOY1.210-0.442
TTM0.7685Y9.916-9.149
5Y9.91610Y11.575-1.659
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6611.896-1.235
MRQ0.7122.115-1.403
TTM0.7682.093-1.325
YOY1.2102.884-1.674
5Y9.9163.542+6.374
10Y11.5753.916+7.659
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Molecular Partners AG ADR.

3.1. Institutions holding Molecular Partners AG ADR

Institutions are holding 2.634% of the shares of Molecular Partners AG ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc1.34910.047744322100
2023-12-31Suvretta Capital Management, LLC1.21750.075640000000
2023-09-30TANG CAPITAL MANAGEMENT LLC0.30440.058410000060247151.5533
2023-12-31Susquehanna International Group, LLP0.0384012618-3957-23.8733
2023-12-31Morgan Stanley - Brokerage Accounts0.0011036700
2023-12-31Rhumbline Advisers0.0008026900
2023-12-31Qube Research & Technologies001600
2023-12-31JPMorgan Chase & Co00110
2023-09-30JANE STREET GROUP, LLC000-16816-100
Total 2.91130.1817956492+39475+4.1%

3.2. Funds holding Molecular Partners AG ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.00330107000
Total 0.00330107000.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Molecular Partners AG ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.658-0.315-52%0.898-173%0.141-567%0.137-581%
Book Value Per Share--5.8716.661-12%8.268-29%4.223+39%3.378+74%
Current Ratio--13.35014.414-7%12.904+3%7.487+78%8.308+61%
Debt To Asset Ratio--0.1110.102+8%0.118-6%0.301-63%0.284-61%
Debt To Equity Ratio--0.1240.114+9%0.135-8%0.516-76%0.449-72%
Dividend Per Share----0%0.005-100%0.001-100%0.001-100%
Eps---0.658-0.526-20%0.982-167%-0.182-72%-0.161-76%
Free Cash Flow Per Share---0.505-0.488-3%0.974-152%-0.089-82%-0.134-74%
Free Cash Flow To Equity Per Share---0.515-0.498-3%0.961-154%0.272-289%0.132-489%
Gross Profit Margin--1.0001.021-2%1.0000%1.033-3%1.017-2%
Intrinsic Value_10Y_max---9.613--------
Intrinsic Value_10Y_min---30.678--------
Intrinsic Value_1Y_max---0.460--------
Intrinsic Value_1Y_min---0.972--------
Intrinsic Value_3Y_max---1.765--------
Intrinsic Value_3Y_min---4.759--------
Intrinsic Value_5Y_max---3.533--------
Intrinsic Value_5Y_min---10.531--------
Market Cap127474684.000-8%137330974.000169018946.350-19%339894463.200-60%460525763.860-70%601853228.505-77%
Net Profit Margin---19.167-16.804-12%-2.962-85%-10.544-45%-5.848-69%
Operating Margin---16.132-15.396-5%-2.873-82%-10.026-38%-5.586-65%
Operating Ratio--16.54826.209-37%6.504+154%10.864+52%4.974+233%
Pb Ratio0.661-8%0.7120.768-7%1.210-41%9.916-93%11.575-94%
Pe Ratio-1.474+7%-1.588-2.517+59%-4.280+170%-7.725+387%-653.739+41074%
Price Per Share3.880-8%4.1805.145-19%10.143-59%13.968-70%18.294-77%
Price To Free Cash Flow Ratio-1.921+7%-2.069-2.647+28%-2.351+14%-34.565+1570%-20.824+906%
Price To Total Gains Ratio-5.895+7%-6.351-1.852-71%10.090-163%-3.694-42%-1.626-74%
Quick Ratio--21.38023.665-10%20.730+3%11.452+87%10.719+99%
Return On Assets---0.100-0.071-29%0.091-210%-0.121+21%-0.094-6%
Return On Equity---0.112-0.079-29%0.109-203%-0.221+97%-0.159+42%
Total Gains Per Share---0.658-0.315-52%0.903-173%0.142-563%0.137-580%
Usd Book Value--192872182.800218852627.400-12%277937901.000-31%140040655.455+38%111641149.971+73%
Usd Book Value Change Per Share---0.658-0.315-52%0.898-173%0.141-567%0.137-581%
Usd Book Value Per Share--5.8716.661-12%8.268-29%4.223+39%3.378+74%
Usd Dividend Per Share----0%0.005-100%0.001-100%0.001-100%
Usd Eps---0.658-0.526-20%0.982-167%-0.182-72%-0.161-76%
Usd Free Cash Flow---16590403.200-16040250.300-3%32016821.700-152%-2935405.980-82%-4395057.169-74%
Usd Free Cash Flow Per Share---0.505-0.488-3%0.974-152%-0.089-82%-0.134-74%
Usd Free Cash Flow To Equity Per Share---0.515-0.498-3%0.961-154%0.272-289%0.132-489%
Usd Market Cap127474684.000-8%137330974.000169018946.350-19%339894463.200-60%460525763.860-70%601853228.505-77%
Usd Price Per Share3.880-8%4.1805.145-19%10.143-59%13.968-70%18.294-77%
Usd Profit---21623496.000-17089175.700-21%32414473.200-167%-6198225.360-71%-5389275.070-75%
Usd Revenue--1128182.4001923485.400-41%51805654.800-98%12725230.620-91%9345828.839-88%
Usd Total Gains Per Share---0.658-0.315-52%0.903-173%0.142-563%0.137-580%
 EOD+3 -5MRQTTM+3 -31YOY+6 -295Y+11 -2510Y+10 -26

4.2. Fundamental Score

Let's check the fundamental score of Molecular Partners AG ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.474
Price to Book Ratio (EOD)Between0-10.661
Net Profit Margin (MRQ)Greater than0-19.167
Operating Margin (MRQ)Greater than0-16.132
Quick Ratio (MRQ)Greater than121.380
Current Ratio (MRQ)Greater than113.350
Debt to Asset Ratio (MRQ)Less than10.111
Debt to Equity Ratio (MRQ)Less than10.124
Return on Equity (MRQ)Greater than0.15-0.112
Return on Assets (MRQ)Greater than0.05-0.100
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Molecular Partners AG ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.904
Ma 20Greater thanMa 503.951
Ma 50Greater thanMa 1004.111
Ma 100Greater thanMa 2004.297
OpenGreater thanClose3.880
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  -8,206493-7,713460-7,252491-6,7616,993232
Gross Profit  -10,404-140-10,544-1,719-12,2622,351-9,91111,0391,128



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CHF. All numbers in thousands.

Summary
Total Assets198,352
Total Liabilities21,923
Total Stockholder Equity176,429
 As reported
Total Liabilities 21,923
Total Stockholder Equity+ 176,429
Total Assets = 198,352

Assets

Total Assets198,352
Total Current Assets192,459
Long-term Assets5,893
Total Current Assets
Cash And Cash Equivalents 186,889
Short-term Investments 119,580
Net Receivables 1,745
Total Current Assets  (as reported)192,459
Total Current Assets  (calculated)308,214
+/- 115,755
Long-term Assets
Property Plant Equipment 5,681
Intangible Assets 212
Long-term Assets  (as reported)5,893
Long-term Assets  (calculated)5,893
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,416
Long-term Liabilities7,507
Total Stockholder Equity176,429
Total Current Liabilities
Short-term Debt 1,208
Accounts payable 1,328
Other Current Liabilities 7,547
Total Current Liabilities  (as reported)14,416
Total Current Liabilities  (calculated)10,083
+/- 4,333
Long-term Liabilities
Capital Lease Obligations 3,652
Long-term Liabilities  (as reported)7,507
Long-term Liabilities  (calculated)3,652
+/- 3,855
Total Stockholder Equity
Common Stock3,635
Retained Earnings -191,755
Other Stockholders Equity 364,549
Total Stockholder Equity (as reported)176,429
Total Stockholder Equity (calculated)176,429
+/-0
Other
Capital Stock3,635
Cash and Short Term Investments 186,889
Common Stock Shares Outstanding 32,854
Current Deferred Revenue4,333
Liabilities and Stockholders Equity 198,352
Net Debt -183,237
Net Invested Capital 176,429
Net Working Capital 178,043
Property Plant and Equipment Gross 22,023
Short Long Term Debt Total 3,652



Balance Sheet

Currency in CHF. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
27,528
27,528
27,528
27,528
48,505
48,505
48,505
194,018
54,849
193,509
54,849
219,395
46,025
200,612
46,025
184,098
36,106
161,048
36,106
144,423
38,789
127,435
38,789
155,156
26,234
134,882
26,234
104,935
46,887
73,330
46,887
187,546
43,167
206,987
176,364
172,668
311,842
299,293
281,164
262,258
244,534
230,493
218,118
198,352
198,352218,118230,493244,534262,258281,164299,293311,842172,668176,364206,98743,167187,54646,88773,33046,887104,93526,234134,88226,234155,15638,789127,43538,789144,42336,106161,04836,106184,09846,025200,61246,025219,39554,849193,50954,849194,01848,50548,50548,50527,52827,52827,52827,528
   > Total Current Assets 
26,948
26,948
26,948
26,948
47,990
47,990
47,990
191,961
54,215
191,230
54,215
216,860
45,389
198,001
45,389
181,555
35,631
158,799
35,631
142,525
38,330
125,768
38,330
153,319
24,980
129,487
24,980
99,921
44,453
68,519
44,453
177,812
41,048
198,069
167,651
164,191
303,608
291,486
273,688
254,752
237,479
223,859
211,933
192,459
192,459211,933223,859237,479254,752273,688291,486303,608164,191167,651198,06941,048177,81244,45368,51944,45399,92124,980129,48724,980153,31938,330125,76838,330142,52535,631158,79935,631181,55545,389198,00145,389216,86054,215191,23054,215191,96147,99047,99047,99026,94826,94826,94826,948
       Cash And Cash Equivalents 
24,032
24,032
24,032
24,032
47,096
47,096
47,096
188,383
48,842
175,631
48,842
195,370
37,434
176,781
37,434
149,735
32,829
118,558
32,829
131,316
24,740
92,667
24,740
98,958
18,928
67,625
18,928
75,712
33,430
47,318
33,430
133,721
17,953
126,566
82,905
71,813
142,019
114,943
69,703
87,946
73,930
63,243
68,399
186,889
186,88968,39963,24373,93087,94669,703114,943142,01971,81382,905126,56617,953133,72133,43047,31833,43075,71218,92867,62518,92898,95824,74092,66724,740131,31632,829118,55832,829149,73537,434176,78137,434195,37048,842175,63148,842188,38347,09647,09647,09624,03224,03224,03224,032
       Short-term Investments 
0
0
0
0
0
0
0
0
5,005
0
5,005
20,020
7,623
19,565
7,623
30,491
2,436
38,299
2,436
9,745
0
29,697
0
0
4,842
55,626
4,842
19,368
10,000
17,093
10,000
40,000
15,250
47,699
71,348
61,000
154,229
170,124
197,431
161,198
158,442
154,952
138,225
119,580
119,580138,225154,952158,442161,198197,431170,124154,22961,00071,34847,69915,25040,00010,00017,09310,00019,3684,84255,6264,8420029,69709,7452,43638,2992,43630,4917,62319,5657,62320,0205,00505,00500000000
       Net Receivables 
2,884
2,884
2,884
2,884
800
800
800
3,199
336
15,084
336
1,343
211
1,276
211
844
288
1,101
288
1,153
12,904
1,148
12,904
51,615
637
6,236
637
2,548
710
4,108
710
2,839
6,432
23,804
13,398
25,726
3,474
2,580
1,730
1,698
1,744
1,510
1,786
1,745
1,7451,7861,5101,7441,6981,7302,5803,47425,72613,39823,8046,4322,8397104,1087102,5486376,23663751,61512,9041,14812,9041,1532881,1012888442111,2762111,34333615,0843363,1998008008002,8842,8842,8842,884
       Other Current Assets 
32
32
32
32
95
95
95
0
32
0
32
0
121
1,654
121
1,329
78
1,942
78
9,745
687
3,404
687
54,361
573
6,236
573
4,841
313
4,108
313
4,091
1,413
0
0
5,652
3,886
3,839
4,824
3,910
3,363
4,154
3,523
3,825
3,8253,5234,1543,3633,9104,8243,8393,8865,652001,4134,0913134,1083134,8415736,23657354,3616873,4046879,745781,942781,3291211,654121032032095959532323232
   > Long-term Assets 
580
580
580
580
514
514
514
2,057
634
2,280
634
2,536
636
2,611
636
2,543
475
2,249
475
1,898
459
1,667
459
1,837
1,254
5,395
1,254
5,014
2,434
4,811
2,434
9,734
2,119
8,918
8,713
8,477
8,234
7,807
7,476
7,506
7,055
6,634
6,185
5,893
5,8936,1856,6347,0557,5067,4767,8078,2348,4778,7138,9182,1199,7342,4344,8112,4345,0141,2545,3951,2541,8374591,6674591,8984752,2494752,5436362,6116362,5366342,2806342,057514514514580580580580
       Property Plant Equipment 
574
574
574
574
507
507
507
2,030
630
2,254
630
2,518
624
2,564
624
2,496
468
2,215
468
1,871
364
1,652
364
1,455
1,061
4,770
1,061
4,242
2,347
4,200
2,347
9,387
2,037
8,621
8,448
8,146
7,949
7,516
7,189
7,235
6,768
6,357
5,919
5,681
5,6815,9196,3576,7687,2357,1897,5167,9498,1468,4488,6212,0379,3872,3474,2002,3474,2421,0614,7701,0611,4553641,6523641,8714682,2154682,4966242,5646242,5186302,2546302,030507507507574574574574
       Intangible Assets 
6
6
6
6
7
7
7
27
4
26
4
17
12
47
12
47
7
34
7
27
96
15
96
382
193
625
193
772
87
0
87
347
83
0
0
330
0
291
287
271
287
277
266
212
212266277287271287291033000833478708777219362519338296159627734747124712174264277776666
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,871
0
0
0
0
0
0
0
0
0
611
0
0
0
0
0
1
285
-7,807
-7,476
-7,506
-7,055
-6,634
-6,185
212
212-6,185-6,634-7,055-7,506-7,476-7,807285100000611000000000-1,8710000000000000000000
> Total Liabilities 
15,449
15,449
15,449
15,449
11,385
11,385
11,385
45,539
16,900
50,539
16,900
67,601
12,076
59,181
12,076
48,303
6,924
42,762
6,924
27,694
15,863
11,096
15,863
63,452
12,699
56,817
12,699
50,796
20,082
42,325
20,082
80,326
16,345
72,349
51,938
65,379
47,345
33,420
29,730
27,092
22,371
24,516
21,909
21,923
21,92321,90924,51622,37127,09229,73033,42047,34565,37951,93872,34916,34580,32620,08242,32520,08250,79612,69956,81712,69963,45215,86311,09615,86327,6946,92442,7626,92448,30312,07659,18112,07667,60116,90050,53916,90045,53911,38511,38511,38515,44915,44915,44915,449
   > Total Current Liabilities 
5,685
5,685
5,685
5,685
5,526
5,526
5,526
22,102
6,612
25,209
6,612
26,447
3,941
22,287
3,941
15,765
3,535
14,997
3,535
14,141
9,216
6,648
9,216
36,865
7,151
34,544
7,151
28,605
14,418
29,474
14,418
57,670
11,716
57,619
39,684
46,865
30,432
23,314
19,046
17,251
15,378
15,670
14,539
14,416
14,41614,53915,67015,37817,25119,04623,31430,43246,86539,68457,61911,71657,67014,41829,47414,41828,6057,15134,5447,15136,8659,2166,6489,21614,1413,53514,9973,53515,7653,94122,2873,94126,4476,61225,2096,61222,1025,5265,5265,5265,6855,6855,6855,685
       Short-term Debt 
0
0
0
0
0
0
0
0
0
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,255
0
1,267
0
1,273
0
1,179
0
1,184
1,186
1,189
1,191
1,193
1,196
1,198
1,201
1,203
1,205
1,208
1,2081,2051,2031,2011,1981,1961,1931,1911,1891,1861,18401,17901,27301,26701,2550000000000000002,352000000000
       Accounts payable 
61
61
61
61
86
86
86
344
308
894
308
1,232
257
2,745
257
1,027
179
1,527
179
716
527
2,288
527
2,108
505
2,949
505
2,019
700
2,303
700
2,800
1,216
10,514
3,798
4,862
4,550
5,549
3,418
997
2,859
2,739
2,103
1,328
1,3282,1032,7392,8599973,4185,5494,5504,8623,79810,5141,2162,8007002,3037002,0195052,9495052,1085272,2885277161791,5271791,0272572,7452571,23230889430834486868661616161
       Other Current Liabilities 
1,164
1,164
1,164
1,164
807
807
807
3,228
765
0
765
3,062
1,065
3,107
1,065
4,259
1,137
2,991
1,137
4,546
1,731
4,360
1,731
6,923
2,069
6,900
2,069
7,009
2,981
5,718
2,981
10,743
3,423
9,754
8,963
12,502
6,754
7,558
6,470
8,647
4,862
5,890
7,000
7,547
7,5477,0005,8904,8628,6476,4707,5586,75412,5028,9639,7543,42310,7432,9815,7182,9817,0092,0696,9002,0696,9231,7314,3601,7314,5461,1372,9911,1374,2591,0653,1071,0653,06276507653,2288078078071,1641,1641,1641,164
   > Long-term Liabilities 
9,764
9,764
9,764
9,764
5,859
5,859
5,859
23,437
10,289
25,329
10,289
41,154
8,135
36,894
8,135
32,538
3,388
27,765
3,388
13,553
6,647
4,448
6,647
26,587
5,548
22,273
5,548
22,191
5,664
12,851
5,664
22,656
4,629
14,730
12,254
18,514
16,913
10,106
10,684
9,841
6,993
8,846
7,370
7,507
7,5077,3708,8466,9939,84110,68410,10616,91318,51412,25414,7304,62922,6565,66412,8515,66422,1915,54822,2735,54826,5876,6474,4486,64713,5533,38827,7653,38832,5388,13536,8948,13541,15410,28925,32910,28923,4375,8595,8595,8599,7649,7649,7649,764
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,211
0
16,617
16,617
15,036
9,285
7,106
13,664
12,362
5,854
6,732
6,189
0
5,797
4,623
0
04,6235,79706,1896,7325,85412,36213,6647,1069,28515,03616,61716,617012,2110000000000000000000000000000
> Total Stockholder Equity
12,079
12,079
12,079
12,079
37,120
37,120
37,120
148,479
37,949
142,971
37,949
151,795
33,949
141,431
33,949
135,795
29,182
118,286
29,182
116,729
22,926
116,339
22,926
91,704
13,535
78,065
13,535
54,139
26,805
31,005
26,805
107,220
26,822
134,638
124,426
107,289
264,497
265,873
251,434
235,166
222,163
205,977
196,209
176,429
176,429196,209205,977222,163235,166251,434265,873264,497107,289124,426134,63826,822107,22026,80531,00526,80554,13913,53578,06513,53591,70422,926116,33922,926116,72929,182118,28629,182135,79533,949141,43133,949151,79537,949142,97137,949148,47937,12037,12037,12012,07912,07912,07912,079
   Common Stock
375
375
375
375
491
491
491
1,964
491
1,964
491
1,964
518
2,072
518
2,072
526
2,079
526
2,104
531
2,118
531
2,123
540
2,138
540
2,160
729
2,181
729
2,915
807
3,227
3,228
3,229
3,233
3,250
3,601
3,604
3,606
3,633
3,633
3,635
3,6353,6333,6333,6063,6043,6013,2503,2333,2293,2283,2278072,9157292,1817292,1605402,1385402,1235312,1185312,1045262,0795262,0725182,0725181,9644911,9644911,964491491491375375375375
   Retained Earnings -191,755-170,827-160,056-142,532-127,780-110,376-95,480-95,317-250,950-232,512-222,210-62,738-195,174-48,794-155,693-48,794-130,870-32,718-105,216-32,718-89,857-22,464-63,566-22,464-60,724-15,181-56,662-15,181-37,265-9,316-30,265-9,316-18,016-4,504-25,052-4,504-17,346-4,337-4,337-4,337-3,513-3,513-3,513-3,513
   Accumulated Other Comprehensive Income 00-981-633-981000000-3,185-10,662-2,6660-2,666-8,881-2,220-7,853-2,220-6,857-1,7140-1,714-6,105-1,5260-1,526-5,105-1,2760-1,276-4,102-1,0260-1,026-3,303-826-826-826-633-633-633-633
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000
   Other Stockholders Equity 
15,850
15,850
15,850
15,850
41,791
41,791
41,791
167,164
42,987
166,058
42,987
171,948
44,023
169,624
44,023
176,093
45,364
172,869
45,364
181,454
46,574
177,787
46,574
186,295
47,933
188,996
47,933
191,730
77,535
184,517
77,535
310,141
91,938
353,621
353,710
355,010
356,581
358,103
358,209
360,323
361,089
363,381
363,403
364,549
364,549363,403363,381361,089360,323358,209358,103356,581355,010353,710353,62191,938310,14177,535184,51777,535191,73047,933188,99647,933186,29546,574177,78746,574181,45445,364172,86945,364176,09344,023169,62444,023171,94842,987166,05842,987167,16441,79141,79141,79115,85015,85015,85015,850



Balance Sheet

Currency in CHF. All numbers in thousands.




Cash Flow

Currency in CHF. All numbers in thousands.




Income Statement

Currency in CHF. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue7,038
Cost of Revenue-0
Gross Profit7,0387,038
 
Operating Income (+$)
Gross Profit7,038
Operating Expense-65,726
Operating Income-61,108-58,688
 
Operating Expense (+$)
Research Development46,731
Selling General Administrative18,995
Selling And Marketing Expenses0
Operating Expense65,72665,726
 
Net Interest Income (+$)
Interest Income3,789
Interest Expense-49
Other Finance Cost-0
Net Interest Income3,740
 
Pretax Income (+$)
Operating Income-61,108
Net Interest Income3,740
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-61,984-60,232
EBIT - interestExpense = -61,157
-61,984
-61,935
Interest Expense49
Earnings Before Interest and Taxes (EBIT)-61,108-61,935
Earnings Before Interest and Taxes (EBITDA)-58,688
 
After tax Income (+$)
Income Before Tax-61,984
Tax Provision-0
Net Income From Continuing Ops-59,634-61,984
Net Income-61,984
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,146
Total Other Income/Expenses Net-876-3,740
 

Technical Analysis of Molecular Partners AG ADR
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Molecular Partners AG ADR. The general trend of Molecular Partners AG ADR is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Molecular Partners AG ADR's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Molecular Partners AG ADR.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.24 < 4.36 < 4.66.

The bearish price targets are: .

Tweet this
Molecular Partners AG ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Molecular Partners AG ADR. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Molecular Partners AG ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Molecular Partners AG ADR. The current macd is -0.10020093.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Molecular Partners AG ADR price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Molecular Partners AG ADR. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Molecular Partners AG ADR price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Molecular Partners AG ADR Daily Moving Average Convergence/Divergence (MACD) ChartMolecular Partners AG ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Molecular Partners AG ADR. The current adx is 19.79.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Molecular Partners AG ADR shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Molecular Partners AG ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Molecular Partners AG ADR. The current sar is 4.70621329.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Molecular Partners AG ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Molecular Partners AG ADR. The current rsi is 47.90. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Molecular Partners AG ADR Daily Relative Strength Index (RSI) ChartMolecular Partners AG ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Molecular Partners AG ADR. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Molecular Partners AG ADR price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Molecular Partners AG ADR Daily Stochastic Oscillator ChartMolecular Partners AG ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Molecular Partners AG ADR. The current cci is -43.57869763.

Molecular Partners AG ADR Daily Commodity Channel Index (CCI) ChartMolecular Partners AG ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Molecular Partners AG ADR. The current cmo is -0.53764369.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Molecular Partners AG ADR Daily Chande Momentum Oscillator (CMO) ChartMolecular Partners AG ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Molecular Partners AG ADR. The current willr is -64.55696203.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Molecular Partners AG ADR is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Molecular Partners AG ADR Daily Williams %R ChartMolecular Partners AG ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Molecular Partners AG ADR.

Molecular Partners AG ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Molecular Partners AG ADR. The current atr is 0.24104295.

Molecular Partners AG ADR Daily Average True Range (ATR) ChartMolecular Partners AG ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Molecular Partners AG ADR. The current obv is 8,896.

Molecular Partners AG ADR Daily On-Balance Volume (OBV) ChartMolecular Partners AG ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Molecular Partners AG ADR. The current mfi is 31.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Molecular Partners AG ADR Daily Money Flow Index (MFI) ChartMolecular Partners AG ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Molecular Partners AG ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Molecular Partners AG ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Molecular Partners AG ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.904
Ma 20Greater thanMa 503.951
Ma 50Greater thanMa 1004.111
Ma 100Greater thanMa 2004.297
OpenGreater thanClose3.880
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Molecular Partners AG ADR with someone you think should read this too:
  • Are you bullish or bearish on Molecular Partners AG ADR? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Molecular Partners AG ADR? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Molecular Partners AG ADR

I send you an email if I find something interesting about Molecular Partners AG ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Molecular Partners AG ADR.

Receive notifications about Molecular Partners AG ADR in your mailbox!